ClinicalTrials.gg
CompletedNCT03538691Updated Oct 12, 2023Results posted

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

A Phase 3 interventional study of Brexpiprazole and Antidepressant therapy in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-10-12.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,149
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
4th of 24
1,149 · median 189
Started
2018
with 3 others
Phase 3
16 of 24
none open now
Registered
18th of 24
by date
Lead sponsor
15 of 24
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 4th largest by enrollment, is one of 4 that started in 2018, is one of 16 in phase 3, and was the 18th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term outcomes remains challenging.

This study will assess the safety, efficacy and tolerability of brexpiprazole as adjunctive therapy to protocol-specific open-label antidepressant therapy.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Brexpiprazole
  • MDD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with both a diagnosis of recurrent major depressive disorder, and in a current major depressive episode of ≥ 8 weeks in duration, as defined by , 5th Edition (DSM-5) and confirmed by both the Mini International Neuropsychiatric Interview (MINI) and an adequate clinical psychiatric evaluation.
  • Participants must have reported a history for the current major depressive episode of an inadequate response to 1 or 2 adequate antidepressant treatments, and participants must currently be taking a protocol-mandated antidepressant treatment at an adequate dose and duration, and most not have reported ≥ 50% improvement. For participants who are currently on an adequate dose of protocol-mandated antidepressant therapy (ADT), but for an inadequate duration, can use the screening period to achieve adequate duration. At Phase A baseline visit, all participants must have either 2 or 3 documented inadequate responses to antidepressant treatment in total for the current episode as defined by the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ).
  • Participants with a Hamilton Rating Scale for Depression (HAM-D17) total score ≥ 18 at the screening visit, and Phase A baseline visits.
  • Participants willing to discontinue all prohibited psychotropic medications to meet protocol-required washouts prior to and during the trial period.

Exclusion criteria

Exclusion Criteria:

  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving medicinal product (IMP).
  • Sexually active males or females of who do not agree to practice 2 different methods of or remain abstinent during the trial and for 30 days after the last dose of IMP.
  • Participants who report treatment with adjunctive antipsychotic medication with an antidepressant for a minimum of 3 weeks during the current major depressive episode.
  • Participants who report allergies or an intolerability (lifetime treatment history) to trial-provided ADTs that have not been prescribed to the participant during the current major depressive episode.
  • Participants who have received electroconvulsive therapy (ECT) for the current major depressive episode.
  • Participants who have had an inadequate response to ECT at any time in the past or who have had a vagus nerve stimulation or deep brain stimulation device implanted at any time for the management of treatment-resistant depression. Participants who have had transcranial magnetic stimulation during the current major depressive episode.
  • Participants with a current need for involuntary commitment or who have been hospitalized within 4 weeks of screening for the current major depressive episode.
  • Participants with a primary diagnosis of:

    1. Schizophrenia Spectrum and Other Psychotic Disorders
    2. Bipolar and Related Disorders
    3. Obsessive Compulsive Disorders
    4. Feeding and Eating Disorders
    5. Neurocognitive Disorders
    6. Panic Disorder
    7. Post-Traumatic Stress Disorder
  • Participants with a current DSM-5 diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder or intellectual disability.
  • Participants experiencing hallucinations, delusions, or any psychotic symptomatology in the current major depressive episode.
  • Participants receiving new onset psychotherapy (individual, group, marriage or family therapy) within 42 days of screening or at any time during participation in the trial.
  • Participants who have met DSM-5 criteria for substance use disorder (moderate or severe) within the past 60 days; including alcohol and benzodiazepines, but excluding nicotine.
  • Participants with hypothyroidism or hyperthyroidism (unless condition has been stabilized with medications for at least the past 90 days) and/or an abnormal result for free T4 at screening.
  • Participants who currently have neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders such as any history of myocardial infarction, congestive heart failure, seropositive status/acquired immunodeficiency syndrome, chronic or C.
  • Participants with diabetes mellitus (IDDM and non-IDDM) are ineligible for the trial unless their condition is stable and well-controlled.
  • Participants with uncontrolled hypertension (DBP > 95 millimetres of mercury [mmHg]) or symptomatic hypotension, or orthostatic hypotension which is defined as a decrease of ≥ 30 mmHg in systolic blood pressure (SBP) and/or decrease of ≥ 20 mmHg in diastolic blood pressure (DBP) after at least 3 minutes standing compared to the previous supine blood pressure OR development of symptoms.
  • Participants with known ischemic heart disease or history of myocardial infarction-or congestive heart failure (whether controlled or uncontrolled).
  • Participants with epilepsy or a history of seizures, except for a single seizure episode.
  • Participants with a positive drug screen for cocaine or other drugs of abuse (excluding known prescription stimulants and other medications and marijuana). Detectable levels of alcohol, marijuana, barbiturates, or opiates in the drug screen are not exclusionary if, in the investigator's documented opinion, the participant does not meet DSM-5 criteria for moderate to severe substance use disorder and the positive test does not signal a clinical condition that would impact the safety of the participant or interpretation of the trial results, and participation is agreed to by the medical monitor prior to treatment.
  • Treatment with a monoamine oxidase inhibitor (MAOI) within 14 day prior to the first dose of IMP in Phase A.
  • Use of benzodiazepines and/or hypnotics (including non-benzodiazepine sleep aids) within 7 days prior to first dose of IMP in Phase A.
  • Use of varenicline within 5 days prior to the first dose of IMP in Phase A.
  • Use of oral (or immediate release intramuscular) neuroleptics within 7 days prior or long-acting approved neuroleptics ≤ 1 full cycle plus 1/2 cycle prior to the first dose of IMP in Phase A.
  • Participants who would be likely to require prohibited concomitant therapy during the trial.
  • Participants who have been exposed to brexpiprazole in any prior clinical trial or has received commercial brexpiprazole (Rexulti).
  • Participants with a history of neuroleptic malignant syndrome or serotonin syndrome.
  • Participants with a history of true allergic response to more than one class of medications.
  • Prisoners or participants who are compulsorily detained for treatment of either a psychiatric or physical illness.
  • Participants who participated in any clinical trial within the last 60 days or who participated in more than 2 clinical trials within the past year.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,149 participants (actual)

Study arms

  • Experimental
    Phase A: Brexpiprazole + ADT

    Participants received brexpiprazole 2 or 3 milligrams per day (mg/day) along with protocol-specified antidepressant therapy (ADT), orally, for 6 to 8 weeks during Phase A. Participants were initially titrated to a target dose of brexpiprazole 2 mg over a 2 to 4-week period. Thereafter, participants who had not met response criteria as defined in the blinded addendum, did not have potentially dose-related adverse events (AEs), and had not achieved the maximum dose of medication had their dose increased up to 3 mg.

    Drug: Brexpiprazole · Drug: Antidepressant therapy

  • Experimental
    Phase B: Brexpiprazole + ADT

    Eligible participants completing Phase A were enrolled in Phase B to receive brexpiprazole 2 or 3 mg/day along with protocol-specified ADT, orally, for 12 weeks.

    Drug: Brexpiprazole · Drug: Antidepressant therapy

  • Experimental
    Phase C: Brexpiprazole + ADT

    Eligible participants completing Phase B received brexpiprazole 2 or 3 mg/day (dose of brexpiprazole that they were receiving at Week 20 of the Stabilization Phase) along with protocol-specified ADT, orally, for up to 26 weeks during Phase C.

    Drug: Brexpiprazole · Drug: Antidepressant therapy

  • Experimental
    Phase C: Placebo + ADT

    Eligible participants completing Phase B received brexpiprazole-matching placebo along with protocol-specified ADT, orally, for up to 26 weeks during Phase C.

    Drug: Antidepressant therapy

Interventions

  • Administered as tablets.

    Also known as: OPC-34712, Rexulti

  • DrugAntidepressant therapy

    Protocol-specified oral ADTs included: citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules.

06

What researchers measure

Primary outcomes

  1. Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum

    Relapse criteria included:At same visit, increase in Montgomery Asberg Depression Rating Scale\[MADRS\] total score(10 items, 0=no symptoms to 6=severe symptoms,total score=0 to 60)of 50% from randomization and Clinical Global Impression-Severity of Illness \[CGI-\](8-point scale of 0=not assessed to 7=most extremely ill)score ≥4,hospitalization for depression, discontinuation for lack of efficacy/worsening of depression, active suicidality(score of ≥4 on MADRS item10 of suicidality)or yes answered on question 4 or 5 of Columbia-Suicide Severity Rating Scale\[C-SSRS\](Suicidal Ideation \[SI\] has 5 questions: wish to be dead,non-specific active suicidal thoughts,active SI with any methods \[not plan\]without intent to act,active SI with some intent to act without specific plan,active SI with specific plan,intent)or yes answered to any question in suicidal behavior section (5 questions:preparatory acts/behavior,aborted attempt,interrupted attempt,actual attempt\[non-fatal\],completed suicide).

    Time frame: Up to 14 days post last dose in Phase C (up to 28 weeks)

Secondary outcomes

  1. Phase C: Change From Baseline for Randomization Phase in Sheehan Disability Scale (SDS) Mean Total Score at Week 46

    The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0=not at all, to 10=extremely. The SDS total score is the mean of the 3 item responses. The SDS total score ranges from 0 to 10, with higher scores indicating greater functional impairment. Baseline was defined as the last available assessment value between Week 14 and Week 20 in Phase B for this outcome measure. Analysis of covariance (ANCOVA) model was used for analysis.

    Time frame: Baseline and Week 46

  2. Phase C: Time-to-functional Relapse Based on SDS Criteria

    Time-to-functional relapse was based on a 30% increase in the SDS mean total score from Phase C Baseline, at least one SDS sub-score at 4 or greater, and an SDS total score ≥7 when all 3 sub-scores were available. The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0=not at all, to 10=extremely. Higher scores of 5 and above are associated with significant functional impairment.

    Time frame: Up to 14 days post last dose in Phase C (up to 28 weeks)

  3. Phase C: Percentage of Participants Meeting Any Relapse Criteria

    Relapse criteria included: At the same visit, increase in MADRS total score (10 items,7-point scale of 0=no symptoms to 6=severe symptoms, total score of 0 to 60) of 50% from randomization and CGI-S (8-point scale ranging from 0=not assessed to 7=most extremely ill) score ≥4, hospitalization for depression, discontinuation for lack of efficacy/worsening of depression, active suicidality (score of ≥4 on MADRS item 10 of suicidality) or answer of yes on question 4 or 5 of C-SSRS (SI has 5 questions: wish to be dead, non-specific active suicidal thoughts, active SI with any methods \[not plan\] without intent to act, active SI with some intent to act without specific plan, active SI with specific plan, intent) or answer of yes to any question in suicidal behavior section (5 questions: preparatory acts/behavior, aborted attempt, interrupted attempt, actual attempt \[non-fatal\], completed suicide). Percentage of participants were rounded off to single decimal point.

    Time frame: Up to 26 weeks in Phase C

  4. Phase C: Percentage of Participants Maintaining Remission

    Participants maintaining remission was defined as MADRS total score ≤10. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants were rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression.

    Time frame: Weeks 21, 23, 25, 29, 33, 37, 41, 45, and 46

  5. Phase C: Change From Baseline for Randomization Phase in MADRS Total Score at Week 46

    The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants were rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A positive change from Baseline indicates worsening of symptoms. Baseline was defined as the last available assessment value in Phase B for this outcome measure. ANCOVA model was used for analysis.

    Time frame: Baseline and Week 46

  6. Phase C: Change From Baseline for Randomization Phase in CGI-S Score at Week 46

    The CGI -S was used to rate the severity of illness for each participant on an 8-point scale ranging from 0 to 7 where 0=not assessed, 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill participants. A positive change from Baseline indicates worsening of illness. Baseline was defined as the last available assessment value in Phase B for this outcome measure. ANCOVA model was used for analysis.

    Time frame: Baseline and Week 46

  7. Phase C: Change From Baseline for Randomization Phase in Each of the SDS Individual Item Scores at Week 46

    The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0=not at all, to 10=extremely. Higher scores of 5 and above are associated with significant functional impairment. A positive change from Baseline indicates worsening of symptoms impacting each area. Baseline was defined as the last available assessment value between Week 14 and Week 20 in Phase B for this outcome measure. ANCOVA model was used for analysis.

    Time frame: Baseline and Week 46

07

Results

Posted Oct 12, 2023

Participant flow

A total of 1149 participants with major depressive disorder (MDD) participated in the study from 13 July 2018 to 29 July 2022.

Phase A: Acute Treatment (up to 8 Weeks)
Participant flow — Phase A: Acute Treatment (up to 8 Weeks)
MilestonePhase A: Brexpiprazole + ADTPhase B: Brexpiprazole + ADTPhase C: Brexpiprazole + ADTPhase C: Placebo + ADT
Started1149000
Phase a safety sample1136000
Completed766000
Not completed383000
Withdrew: Lost to follow-up24000
Withdrew: Adverse event82000
Withdrew: Subject withdrew consent54000
Withdrew: Death1000
Withdrew: Non-compliance with study drug9000
Withdrew: Lack of efficacy185000
Withdrew: Protocol deviation12000
Withdrew: Physician decision1000
Withdrew: Reason not specified (not due to coronavirus disease 2019 [covid-19] restriction)15000
Phase B: Stabilization (12 Weeks)
Participant flow — Phase B: Stabilization (12 Weeks)
MilestonePhase A: Brexpiprazole + ADTPhase B: Brexpiprazole + ADTPhase C: Brexpiprazole + ADTPhase C: Placebo + ADT
Started076600
Phase b safety sample076500
Completed048900
Not completed027700
Withdrew: Lost to follow-up0500
Withdrew: Adverse event05200
Withdrew: Subject withdrew consent04700
Withdrew: Non-compliance with study drug0900
Withdrew: Lack of efficacy013600
Withdrew: Pregnancy0100
Withdrew: Protocol deviation0900
Withdrew: Physician decision0600
Withdrew: Due to covid-19 restriction0100
Withdrew: Reason not specified (not due to covid-19 restriction)01100
Phase C:Randomized Withdrawal (26 Weeks)
Participant flow — Phase C:Randomized Withdrawal (26 Weeks)
MilestonePhase A: Brexpiprazole + ADTPhase B: Brexpiprazole + ADTPhase C: Brexpiprazole + ADTPhase C: Placebo + ADT
Started00240249
Phase c safety sample00240248
Completed00120131
Not completed00120118
Withdrew: Lost to follow-up00164
Withdrew: Adverse event0066
Withdrew: Subject withdrew consent00619
Withdrew: Non-compliance with study drug0012
Withdrew: Non-compliant participants003228
Withdrew: Pregnancy0010
Withdrew: Lack of efficacy (phase c mdd relapse)005452
Withdrew: Physician decision0001
Withdrew: Reason not specified (not due to covid-19 restriction)0046

Outcome measures

PrimaryPhase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum

Relapse criteria included:At same visit, increase in Montgomery Asberg Depression Rating Scale\[MADRS\] total score(10 items, 0=no symptoms to 6=severe symptoms,total score=0 to 60)of 50% from randomization and Clinical Global Impression-Severity of Illness \[CGI-\](8-point scale of 0=not assessed to 7=most extremely ill)score ≥4,hospitalization for depression, discontinuation for lack of efficacy/worsening of depression, active suicidality(score of ≥4 on MADRS item10 of suicidality)or yes answered on question 4 or 5 of Columbia-Suicide Severity Rating Scale\[C-SSRS\](Suicidal Ideation \[SI\] has 5 questions: wish to be dead,non-specific active suicidal thoughts,active SI with any methods \[not plan\]without intent to act,active SI with some intent to act without specific plan,active SI with specific plan,intent)or yes answered to any question in suicidal behavior section (5 questions:preparatory acts/behavior,aborted attempt,interrupted attempt,actual attempt\[non-fatal\],completed suicide).

Time frame:
Up to 14 days post last dose in Phase C (up to 28 weeks)
Reported as:
Median · days
Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum
daysPhase C: Brexpiprazole + ADTPhase C: Placebo + ADT
Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum63.0 (8 to 185)63.0 (8 to 190)
Statistical analysis
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · Log Rank · p = 0.5100 · Hazard ratio (hr): 1.138 · 95% CI 0.776 to 1.669The hazard ratio and 95% confidence interval (CI) were derived from the Cox proportional hazard model with treatment as fixed effect.
SecondaryPhase C: Change From Baseline for Randomization Phase in Sheehan Disability Scale (SDS) Mean Total Score at Week 46

The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0=not at all, to 10=extremely. The SDS total score is the mean of the 3 item responses. The SDS total score ranges from 0 to 10, with higher scores indicating greater functional impairment. Baseline was defined as the last available assessment value between Week 14 and Week 20 in Phase B for this outcome measure. Analysis of covariance (ANCOVA) model was used for analysis.

Time frame:
Baseline and Week 46
Reported as:
Least squares mean · score on a scale
Phase C: Change From Baseline for Randomization Phase in Sheehan Disability Scale (SDS) Mean Total Score at Week 46
score on a scalePhase C: Brexpiprazole + ADTPhase C: Placebo + ADT
Phase C: Change From Baseline for Randomization Phase in Sheehan Disability Scale (SDS) Mean Total Score at Week 460.72 ± 0.180.48 ± 0.18
Statistical analysis
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · ANCOVA · p = 0.2393 (P-value was derived from an ANCOVA model with treatment, pooled center as factor and Baseline value as covariance.) · Least squares (ls) mean difference: 0.23 · 95% CI -0.16 to 0.62
SecondaryPhase C: Time-to-functional Relapse Based on SDS Criteria

Time-to-functional relapse was based on a 30% increase in the SDS mean total score from Phase C Baseline, at least one SDS sub-score at 4 or greater, and an SDS total score ≥7 when all 3 sub-scores were available. The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0=not at all, to 10=extremely. Higher scores of 5 and above are associated with significant functional impairment.

Time frame:
Up to 14 days post last dose in Phase C (up to 28 weeks)
Reported as:
Median · days
Phase C: Time-to-functional Relapse Based on SDS Criteria
daysPhase C: Brexpiprazole + ADTPhase C: Placebo + ADT
Phase C: Time-to-functional Relapse Based on SDS Criteria36.0 (6 to 185)35.0 (8 to 176)
Statistical analysis
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · Log Rank · p = 0.3086 · Hazard ratio (hr): 1.177 · 95% CI 0.857 to 1.615The hazard ratio and 95% CI were derived from the Cox proportional hazard model with treatment as fixed effect.
SecondaryPhase C: Percentage of Participants Meeting Any Relapse Criteria

Relapse criteria included: At the same visit, increase in MADRS total score (10 items,7-point scale of 0=no symptoms to 6=severe symptoms, total score of 0 to 60) of 50% from randomization and CGI-S (8-point scale ranging from 0=not assessed to 7=most extremely ill) score ≥4, hospitalization for depression, discontinuation for lack of efficacy/worsening of depression, active suicidality (score of ≥4 on MADRS item 10 of suicidality) or answer of yes on question 4 or 5 of C-SSRS (SI has 5 questions: wish to be dead, non-specific active suicidal thoughts, active SI with any methods \[not plan\] without intent to act, active SI with some intent to act without specific plan, active SI with specific plan, intent) or answer of yes to any question in suicidal behavior section (5 questions: preparatory acts/behavior, aborted attempt, interrupted attempt, actual attempt \[non-fatal\], completed suicide). Percentage of participants were rounded off to single decimal point.

Time frame:
Up to 26 weeks in Phase C
Reported as:
Number · percentage of participants
Phase C: Percentage of Participants Meeting Any Relapse Criteria
percentage of participantsPhase C: Brexpiprazole + ADTPhase C: Placebo + ADT
Phase C: Percentage of Participants Meeting Any Relapse Criteria22.520.6
Statistical analysis
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · Chi-squared · p = 0.6030
SecondaryPhase C: Percentage of Participants Maintaining Remission

Participants maintaining remission was defined as MADRS total score ≤10. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants were rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression.

Time frame:
Weeks 21, 23, 25, 29, 33, 37, 41, 45, and 46
Reported as:
Number · percentage of participants
Phase C: Percentage of Participants Maintaining Remission
percentage of participantsPhase C: Brexpiprazole + ADTPhase C: Placebo + ADT
Week 2190.3491.3
Week 2385.2282.7
Week 2584.7982.6
Week 2979.8985.5
Week 3388.5588.4
Week 3787.9289.0
Week 4184.7889.4
Week 4588.1489.0
Week 4690.9191.7
Statistical analysis
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · Chi-squared · p = 0.7081
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · Chi-squared · p = 0.4589
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · Chi-squared · p = 0.5314
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · Chi-squared · p = 0.1433
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · Chi-squared · p = 0.9636
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · Chi-squared · p = 0.7596
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · Chi-squared · p = 0.2402
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · Chi-squared · p = 0.8363
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · Chi-squared · p = 0.8308
SecondaryPhase C: Change From Baseline for Randomization Phase in MADRS Total Score at Week 46

The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants were rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A positive change from Baseline indicates worsening of symptoms. Baseline was defined as the last available assessment value in Phase B for this outcome measure. ANCOVA model was used for analysis.

Time frame:
Baseline and Week 46
Reported as:
Least squares mean · score on a scale
Phase C: Change From Baseline for Randomization Phase in MADRS Total Score at Week 46
score on a scalePhase C: Brexpiprazole + ADTPhase C: Placebo + ADT
Phase C: Change From Baseline for Randomization Phase in MADRS Total Score at Week 464.09 ± 0.754.21 ± 0.73
Statistical analysis
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · ANCOVA · p = 0.8806 · Ls mean difference: -0.12 · 95% CI -1.73 to 1.49P-value was derived from an ANCOVA model with treatment, pooled center as factor and Baseline value as covariance.
SecondaryPhase C: Change From Baseline for Randomization Phase in CGI-S Score at Week 46

The CGI -S was used to rate the severity of illness for each participant on an 8-point scale ranging from 0 to 7 where 0=not assessed, 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill participants. A positive change from Baseline indicates worsening of illness. Baseline was defined as the last available assessment value in Phase B for this outcome measure. ANCOVA model was used for analysis.

Time frame:
Baseline and Week 46
Reported as:
Least squares mean · score on a scale
Phase C: Change From Baseline for Randomization Phase in CGI-S Score at Week 46
score on a scalePhase C: Brexpiprazole + ADTPhase C: Placebo + ADT
Phase C: Change From Baseline for Randomization Phase in CGI-S Score at Week 460.56 ± 0.100.53 ± 0.09
Statistical analysis
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · ANCOVA · p = 0.7956 · Ls mean difference: 0.03 · 95% CI -0.18 to 0.24P-value was derived from an ANCOVA model with treatment, pooled center as factor and Baseline value as covariance.
SecondaryPhase C: Change From Baseline for Randomization Phase in Each of the SDS Individual Item Scores at Week 46

The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0=not at all, to 10=extremely. Higher scores of 5 and above are associated with significant functional impairment. A positive change from Baseline indicates worsening of symptoms impacting each area. Baseline was defined as the last available assessment value between Week 14 and Week 20 in Phase B for this outcome measure. ANCOVA model was used for analysis.

Time frame:
Baseline and Week 46
Reported as:
Least squares mean · score on a scale
Phase C: Change From Baseline for Randomization Phase in Each of the SDS Individual Item Scores at Week 46
score on a scalePhase C: Brexpiprazole + ADTPhase C: Placebo + ADT
Work/School0.46 ± 0.220.31 ± 0.23
Social Life0.91 ± 0.190.56 ± 0.19
Family Life0.78 ± 0.190.52 ± 0.19
Statistical analysis
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · ANCOVA · p = 0.5223 (P-value was derived from an ANCOVA model with treatment, pooled center as factor and Baseline value as covariance.) · Ls mean difference: 0.15 · 95% CI -0.31 to 0.61
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · ANCOVA · p = 0.0904 (P-value was derived from an ANCOVA model with treatment, pooled center as factor and Baseline value as covariance.) · Ls mean difference: 0.36 · 95% CI -0.06 to 0.77
  • Phase C: Brexpiprazole + ADT vs Phase C: Placebo + ADT · ANCOVA · p = 0.2289 (P-value was derived from an ANCOVA model with treatment, pooled center as factor and Baseline value as covariance.) · Ls mean difference: 0.25 · 95% CI -0.16 to 0.67

Adverse events

Collected over From first dose of study drug to 21 days after the last dose (Up to 49 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase A: Brexpiprazole + ADT1/1,149 (0.1%)10/1,136 (0.9%)398/1,136 (35%)
Phase B: Brexpiprazole + ADT0/766 (0%)12/765 (1.6%)163/765 (21.3%)
Phase C: Brexpiprazole + ADT0/240 (0%)1/240 (0.4%)25/240 (10.4%)
Phase C: Placebo + ADT0/249 (0%)3/248 (1.2%)13/248 (5.2%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventPhase A: Brexpiprazole + ADTPhase B: Brexpiprazole + ADTPhase C: Brexpiprazole + ADTPhase C: Placebo + ADT
Anaphylactic shockImmune system disorders0/11360/7651/2400/248
CataractEye disorders0/11360/7650/2401/248
Dislocation of vertebraInjury, poisoning and procedural complications0/11360/7650/2401/248
EpicondylitisInjury, poisoning and procedural complications0/11360/7650/2401/248
FallInjury, poisoning and procedural complications0/11360/7650/2401/248
BursitisMusculoskeletal and connective tissue disorders0/11360/7650/2401/248
Myocardial infarctionCardiac disorders0/11361/7650/2400/248
Abdominal pain upperGastrointestinal disorders0/11361/7650/2400/248
HaematemesisGastrointestinal disorders0/11361/7650/2400/248
Acute hepatic failureHepatobiliary disorders0/11361/7650/2400/248
Most frequent other events
Most frequent other events
EventPhase A: Brexpiprazole + ADTPhase B: Brexpiprazole + ADTPhase C: Brexpiprazole + ADTPhase C: Placebo + ADT
Weight increasedInvestigations0/1136122/76525/24013/248
HeadacheNervous system disorders113/113641/7650/2400/248
AkathisiaNervous system disorders109/11360/7650/2400/248
SomnolenceNervous system disorders90/11360/7650/2400/248
InsomniaPsychiatric disorders72/11360/7650/2400/248
NauseaGastrointestinal disorders64/11360/7650/2400/248
Increased appetiteMetabolism and nutrition disorders60/11360/7650/2400/248

Baseline characteristics

Enrolled Sample included all participants who signed the informed consent form and entered Phase A.

Age, Continuous
Age, Continuous(years)Phase A: Brexpiprazole + ADT
Mean42.3 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)Phase A: Brexpiprazole + ADT
Female734
Male415
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase A: Brexpiprazole + ADT
Hispanic or Latino110
Not Hispanic or Latino968
Unknown or Not Reported71
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase A: Brexpiprazole + ADT
American Indian or Alaska Native5
Asian22
Native Hawaiian or Other Pacific Islander5
Black or African American159
White868
More than one race0
Unknown or Not Reported90
08

Study locations

1 site
  • For additional information regarding sites, contact 844-687-8522
    Los Angeles, California 90024, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jul 2022, 47 months.

Results were first posted in Oct 2023, 1 year 3 months after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 47 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2018
First posted
May 29, 2018
StartActual
Jul 13, 2018
Primary completionActual
Jul 8, 2022
CompletionActual
Jul 29, 2022
Results first posted
Oct 12, 2023
Last update
Oct 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03538691
Responsible party
Sponsor
First posted
May 29, 2018
Start date
Jul 13, 2018
Primary completion
Jul 8, 2022
Completion
Jul 29, 2022
Results posted
Oct 12, 2023
Last update
Oct 12, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion